Hovione New Jersey Site Expansion - Opening Ceremony
Hovione invests over €30m in the USA
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione invests over €30m in the USA
Pharmaceutical Technology, 2 Junho 2021
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Hovione has completed significant expansions at its facilities in New Jersey, USA, and Cork, Ireland.
Hovione is expanding its scientific know-how and industrial production capabilities on a variety of technologies to widen its ability to provide customized solutions for advanced APIs (aAPI™).
Hovione offers simple, patented and globally competitive dry powder inhalers – Disposable, Capsule, Blister and Large Dose DPIs – which are available for fully integrated turn-key development with formulation and for licensing.
C&EN, 26 September 2021
High Performance, High-Dose Capsule DPI.